1.      Beghetti M., Schulze-Neick I., Berger R.M., et al. Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: insights from the Global TOPP Registry. Int J Cardiol 2016; 203: 325–330.

2.      Chin K.M., Gaine S.P., Gerges C., et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024. doi: 10.1183/13993003.01325.

3.      Danhaive O., Galambos C., Lakshminrusimha S., et al. Pulmonary hypertension in developmental lung diseases. Clin Perinatol 2024; 51: 217–235.

4.      Douwes J.M., Zijlstra W.M.H., Rosenzweig E.B., et al. Parenteral prostanoids in pediatric pulmonary arterial hypertension: start early, dose high, combine. Ann Am Thorac Soc 2022; 19: 227–237.

5.      Eichstaedt C.A., Belge C., Chung W.K., et al. Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement. Eur Respir J 2023; 61: 2201471.

6.      Haarman M.G., Douwes J.M., Ploegstra M.J., et al. The clinical value of proposed risk stratification tools in pediatric pulmonary arterial hypertension. Am J Respir Crit Care Med 2019; 200: 1312–1315.

7.      Haarman M.G., Lévy M., Roofthooft M.T.R., et al. Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension. Eur Respir J 2021; 57: 2001120.

8.      Humbert M., Kovacs G., Hoeper M.M., et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023; 61: 2200879.

9.      İnci Yıldırım A, İdiopatik ve Herediter Pulmoner Hipertansiyon. Türkiye Klinikleri; 2021. p.125-30

10.  Ivy D., Beghetti M., Juaneda-Simian E., et al. A randomized study of safety and efficacy of two doses of ambrisentan to treat pulmonary arterial hypertension in pediatric patients. J Pediatr X 2020; 5: 100055.

11.  Ivy D., Bonnet D., Berger R.M.F., et al. Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study. Pulm Circ 2021; 11: 20458940211024955.

12.  Ivy D., Rosenzweig E.B., Abman S.H., Beghetti M., Bonnet D., Douwes J.M., et al.. Embracing the challenges of neonatal and paediatric pulmonary hypertension. Eur Respir J. 2024. doi: 10.1183/13993003.01345.

13.  Jain A., Giesinger R.E., Dakshinamurti S., et al. Care of the critically ill neonate with hypoxemic respiratory failure and acute pulmonary hypertension: framework for practice based on consensus opinion of neonatal hemodynamics working group. J Perinatol 2022; 42: 3–13.

14.  Kovacs G., Bartolome S., Denton C.P., et al. Definition, classification and diagnosis of pulmonary hypertension. Eur Respir J. 2024. doi: 10.1183/13993003.01324.

15.  Lokhorst C., van der Werf S., Berger R.M.F., et al. Risk stratification in adult and pediatric pulmonary arterial hypertension: a systematic review. Front Cardiovasc Med 2022; 9: 1035453.

16.  Pektas A., Pektas B.M., Kula S.. Childhood pulmonary arterial hypertension: National registry study. Cardiol Young 2016; 26: 693–697. doi: 10.1017/S1047951115001043.

17.  Ploegstra M.J., Zijlstra W.M.H., Douwes J.M., et al. prognostik factors in pediatric pulmonary arterial hypertension: a systematic review and meta-analysis. Int J Cardiol 2015; 184: 198–207.

18.  Rosenzweig E.B., Abman S.H., Adatia I., Beghetti M., Bonnet D., Haworth S., et al.. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J 2019; 53: 1801916. doi: 10.1183/13993003.01916.

19.  Rosenzweig E.B., Bates A., Mullen M.P., et al. Cardiac catheterization and hemodynamics in a multicenter cohort of children with pulmonary hypertension. Ann Am Thorac Soc 2022; 19: 1000–1012.

20.  Simonneau G., Montani D., Celermajer D.S., et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913.

21.  Welch C.L., Aldred M.A., Balachandar S., et al. Defining the clinical validity of genes reported to cause pulmonary arterial hypertension. Genet Med 2023; 25: 100925.